Dopamine Receptors in Cancer: Are They Valid Therapeutic Targets?
The dopamine receptors (DRs) family includes 5 members with differences in signal transduction and ligand affinity. Abnormal DRs expression has been correlated multiple tumors with their clinical outcome. Thus, it has been proposed that DRs-targeting drugs—developed for other diseases as schizophren...
Main Authors: | Arely Rosas-Cruz BSc, Nohemí Salinas-Jazmín PhD, Marco A. Velasco- Velázquez PhD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-07-01
|
Series: | Technology in Cancer Research & Treatment |
Online Access: | https://doi.org/10.1177/15330338211027913 |
Similar Items
-
Low-Density Lipoprotein Receptor–Related Protein-1 Is a Therapeutic Target in Acute Myocardial Infarction
by: Stefano Toldo, PhD, et al.
Published: (2017-10-01) -
Targeting dopamine receptor D2 as a novel therapeutic strategy in endometrial cancer
by: Stuart R. Pierce, et al.
Published: (2021-02-01) -
Therapeutic Potential of a Polymer-Encapsulated L-Dopa and Dopamine-Producing Cell Line in Rodent and Primate Models of Parkinson's Disease
by: Mark D. Lindner Ph.D., et al.
Published: (1998-03-01) -
Therapeutic Potential of Selenium and Selenium Compounds in Cervical Cancer
by: Ewa Jablonska PhD, et al.
Published: (2021-03-01) -
Phosphatidylserine-Targeted Nanotheranostics for Brain Tumor Imaging and Therapeutic Potential
by: Lulu Wang MD, PhD, et al.
Published: (2017-05-01)